Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NOSEVAC

Financiado

Cerrado

INNOVATIVE NASAL VACCINES TO PREVENT PATHOGEN COLONIZATION AND INFECTION IN THE...

INNOVATIVE NASAL VACCINES TO PREVENT PATHOGEN COLONIZATION AND INFECTION IN THE UPPER RESPIRATORY TRACT Bacterial and viral respiratory infections are a leading cause of morbidity and mortality worldwide. Streptococcus pneumoniae and Bordetella pertussis, influenza virus and SARS-CoV-2, are responsible for diseases with major public... ver más

30/04/2028

EUROPEAN VACCINE I...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

EUROPEAN VACCINE INITIATIVE E.V No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-01

HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the nex... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 3 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

EUROPEAN VACCINE INITIATIVE...

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PnuBioVax PnuBioVax next generation vaccine for a personalised and e... 71K€ Cerrado

SAF2008-00733 SELECCION DE CANDIDATOS PROTEICOS PARA VACUNAS CONTRA STREPT... 121K€ Cerrado

DailySAM Understanding respiratory tract infections through minimally... 2M€ Cerrado

PNEUMOPATH A comprehensive dissection of pneumococcal host interactions 4M€ Cerrado

SAF2017-88664-R ENZIBIOTICOS CONTRA BACTERIAS PATOGENAS RESPIRATORIAS FORMAD... 145K€ Cerrado

CHILD-INNOVAC NASAL VACCINATION AGAINST RESPIRATORY INFECTIONS IN YOUNG CH... 7M€ Cerrado

Duración del proyecto: 59 meses Fecha Inicio: 2023-05-01
Fecha Fin: 2028-04-30

Líder del proyecto

EUROPEAN VACCINE INITIATIVE E.V No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Bacterial and viral respiratory infections are a leading cause of morbidity and mortality worldwide. Streptococcus pneumoniae and Bordetella pertussis, influenza virus and SARS-CoV-2, are responsible for diseases with major public health impact: community-acquired pneumonia, whooping cough, influenza and COVID-19, respectively. Vaccines against some of these diseases, administered by intramuscular or subcutaneous injection, do not prevent colonization or infection of the upper respiratory tract (URT), and therefore have limited impact on pathogen transmission.The NOSEVAC consortium aims to develop and assess innovative nasal vaccine platforms as a novel concept to block the earliest stage of infection, thereby inhibiting URT colonisation, transmission and disease. The project builds on a unique consortium of 12 renowned and complementary teams from the EU, UK and Switzerland.NOSEVAC’s objectives are to:•Develop vaccine formulations for nasal delivery of RNA- and protein-based antigens•Discover bacterial antigens that promote colonization of the URT•Use a combination of in vitro and in vivo models for optimal evaluation of vaccines efficacy•Identify key host immune factors required for long-term protection of the URT in human •Deliver two nasal vaccine candidates to fight S. pneumoniae and B. pertussis infection, and a single bivalent vaccine to prevent influenza and COVID-19•Address acceptability of nasal vaccinationExpected outcomes include (1) strengthening innovation in Europe by enriching the pipeline for novel vaccines against (new) respiratory infections, (2) increasing knowledge on the mechanisms underlying URT colonization, infection and immunity, and (3) evaluating nasal vaccine acceptability by stakeholders. NOSEVAC will develop strategic research avenues to fight respiratory pathogens including those with epidemic potential and will facilitate evidence-based decision making to policy makers and investors.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores